Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E |
Therapy | Dabrafenib |
Indication/Tumor Type | papillary craniopharyngioma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | papillary craniopharyngioma | predicted - sensitive | Dabrafenib | Case Reports/Case Series | Actionable | In a clinical case study, Tafinlar (dabrafenib) treatment resulted in a complete response of the solid internal nodular enhancement and symptom improvement in a patient with papillary craniopharyngioma harboring BRAF V600E (PMID: 31666933). | 31666933 |
BRAF V600E | papillary craniopharyngioma | predicted - sensitive | Dabrafenib | Case Reports/Case Series | Actionable | In a clinical case study, Tafinlar (dabrafenib) treatment resulted in decreased size of the cystic and solid enhancing components of the tumor in a patient with papillary craniopharyngioma harboring BRAF V600E, with stable disease continuing 1 year after discontinuation of treatment (PMID: 29701552). | 29701552 |
PubMed Id | Reference Title | Details |
---|---|---|
(31666933) | Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report. | Full reference... |
(29701552) | Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report. | Full reference... |